Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
15 competitors in Type 2 Diabetes Mellitus
No patent data available. Pre-approval drugs may not have Orange Book listings.
Steglatro
Steglatro is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. in addition to other medicinal products for the treatment of diabetes.
View on EMADiabetic Retinopathy
Osteoporosis
Cardiovascular Disease
Malignant Neoplasms of Male Genital Organs
HPV Positive Oropharyngeal Squamous Cell Carcinoma